<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003293" GROUP_ID="GYNAECA" ID="534200120410524742" MERGED_FROM="" MODIFIED="2015-02-11 12:38:27 +0000" MODIFIED_BY="Tracey Bishop" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-08-07 14:07:18 +0100" NOTES_MODIFIED_BY="Clare Jess" REVIEW_NO="C008" REVMAN_SUB_VERSION="5.0.15" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2015-02-11 12:38:27 +0000" MODIFIED_BY="Tracey Bishop">
<TITLE>Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma</TITLE>
<CONTACT MODIFIED="2015-02-11 12:38:27 +0000" MODIFIED_BY="Tracey Bishop"><PERSON ID="5208" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Vivien</FIRST_NAME><LAST_NAME>Bramwell</LAST_NAME><POSITION>Head of Medical Oncology</POSITION><EMAIL_1>vivienbr@cancerboard.ab.ca</EMAIL_1><ADDRESS><DEPARTMENT>Medical Oncology</DEPARTMENT><ORGANISATION>Tom Baker Cancer Centre</ORGANISATION><ADDRESS_1>1331 - 29th Street</ADDRESS_1><CITY>NW Calgary</CITY><ZIP>T2N  4N2</ZIP><REGION>AB</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>403 944-1707</PHONE_1><FAX_1>403 283-1651</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2015-02-11 12:38:27 +0000" MODIFIED_BY="Tracey Bishop"><PERSON ID="5208" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Vivien</FIRST_NAME><LAST_NAME>Bramwell</LAST_NAME><POSITION>Head of Medical Oncology</POSITION><EMAIL_1>vivienbr@cancerboard.ab.ca</EMAIL_1><ADDRESS><DEPARTMENT>Medical Oncology</DEPARTMENT><ORGANISATION>Tom Baker Cancer Centre</ORGANISATION><ADDRESS_1>1331 - 29th Street</ADDRESS_1><CITY>NW Calgary</CITY><ZIP>T2N  4N2</ZIP><REGION>AB</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>403 944-1707</PHONE_1><FAX_1>403 283-1651</FAX_1></ADDRESS></PERSON><PERSON ID="13669" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Dale</FIRST_NAME><LAST_NAME>Anderson</LAST_NAME><POSITION>Research Coordinator</POSITION><ADDRESS><ORGANISATION>Program in Evidence-based Care</ORGANISATION><ADDRESS_1>1200 Main Street West</ADDRESS_1><ADDRESS_2>HSC-2C8</ADDRESS_2><CITY>Hamilton</CITY><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+ 1 905 525 9140 ext: 22971</PHONE_1><FAX_1>+ 1 905 577 0017</FAX_1></ADDRESS></PERSON><PERSON ID="13677" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Manya</FIRST_NAME><LAST_NAME>Charette</LAST_NAME><EMAIL_1>Charet@mcmaster.ca</EMAIL_1><ADDRESS><ORGANISATION>Program in Evidence-based Care</ORGANISATION><ADDRESS_1>1200 Main Street West</ADDRESS_1><ADDRESS_2>HSC-2C8</ADDRESS_2><CITY>Hamilton</CITY><ZIP>L8N 3Z5</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+ 1 905 525 9140 ext: 22971</PHONE_1><FAX_1>+ 1 905 577 0017</FAX_1></ADDRESS></PERSON><GROUP ID="9D365AE382E26AA2013849DF935D7A15"><GROUP_NAME>Sarcoma Disease Site Group</GROUP_NAME><ADDRESS><DEPARTMENT>Program in Evidence-Based Care (PEBC)</DEPARTMENT><ORGANISATION>McMaster University</ORGANISATION><ADDRESS_1>1280 Main Street West</ADDRESS_1><ADDRESS_2>Downtown Campus, 3rd Floor</ADDRESS_2><CITY>Hamilton</CITY><ZIP>L8S 4L8</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY></ADDRESS></GROUP></CREATORS>
<DATES MODIFIED="2008-08-07 15:11:34 +0200" MODIFIED_BY="Clare Jess">
<UP_TO_DATE>
<DATE DAY="29" MONTH="9" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="29" MONTH="9" YEAR="2006"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2001"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2003"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2003"/>
</DATES>
<WHATS_NEW MODIFIED="2015-02-11 12:38:27 +0000" MODIFIED_BY="Tracey Bishop"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-02-11 12:38:27 +0000" MODIFIED_BY="Tracey Bishop"><DATE DAY="11" MONTH="2" YEAR="2015"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY>

</WHATS_NEW>
<HISTORY MODIFIED="2015-02-11 12:38:27 +0000" MODIFIED_BY="Tracey Bishop"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-02-11 12:38:27 +0000" MODIFIED_BY="Tracey Bishop"><DATE DAY="27" MONTH="3" YEAR="2014"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-03-27 11:34:04 +0000" MODIFIED_BY="Tracey Bishop">
<DATE DAY="7" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-08-07 13:51:33 +0100" MODIFIED_BY="Clare Jess">
<DATE DAY="29" MONTH="8" YEAR="2006"/>
<DESCRIPTION>
<P>The literature search as described in the search strategy sections was updated on 29 September 2006. No new relevant studies were found.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="27" MONTH="7" YEAR="2001"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Cancer Care Ontario</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Ontario Ministry of Health and Long-Term Care</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-08-07 14:07:18 +0100" MODIFIED_BY="Clare Jess">
<SUMMARY>
<TITLE>Additional chemotherapy with doxorubicin marginally improves tumour response but increases side effects with no improvement in survival</TITLE>
<SUMMARY_BODY>
<P>Doxorubicin is commonly used as palliative chemotherapy for patients with advanced or metastatic soft tissue sarcoma (cancer of muscle/tendon/fat/blood vessel). This review was conducted to find out if combining doxorubicin with other drugs is more effective than doxorubicin alone. Eight studies were considered together, which showed if combination chemotherapy is given: (1) tumour shrinkage was marginally better than in patients treated with doxorubicin alone; (2) survival was no different; and (3) side effects were worse than for patients treated with doxorubicin alone</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Considerable controversy exists as to whether any benefit of doxorubicin-based combination chemotherapy outweighs increased toxic effects, inconvenience, and additional costs, compared to single-agent doxorubicin. There is substantial variation in clinical practice in the treatment of patients with locally advanced and metastatic soft tissue sarcoma (STS).</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine:<BR/>1) the effect, if any on response rate or survival, by using doxorubicin-based combination chemotherapy compared with single-agent doxorubicin for the treatment of patients with incurable locally advanced or metastatic STS<BR/>2)if combination chemotherapy is associated with increased adverse effects compared with single-agent doxorubicin in this setting.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched CENTRAL (Cochrane Library, issue 4, 2002), MEDLINE (1966 to October 2002), CANCER LIT (1975 to October 2002), reference lists, the Physician Data Query (PDQ) clinical trials database, and the American Society of Clinical Oncology (ASCO) Annual Meeting Proceedings (1995 to 2002). </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomized controlled trials (RCTs) comparing single-agent doxorubicin with doxorubicin-based combination chemotherapy in adults with locally advanced or metastatic STS requiring palliative chemotherapy. Abstracts and full reports published in English were eligible.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Data were abstracted and assessed by two reviewers. Response and survival data were pooled. Data on adverse effects was tabulated.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Data on 2281 participants from eight RCTs were available from reports of single-agent doxorubicin versus doxorubicin-based combination chemotherapy. Meta-analysis using the fixed effect model detected a higher tumour response rate with combination chemotherapy compared with single-agent chemotherapy (odds ratio [OR= 1.29; 95% confidence interval [CI], 1.03 to 1.60; p = 0.03), but the OR from a pooled analysis using the random effects model and the same data did not achieve statistical significance (OR= 1.26; 95% CI, 0.96 to 1.67; p = 0.10). No significant difference between the two regimens was detected in the pooled one-year mortality rate (OR = 0.87; 95% CI, 0.73 to 1.05; p=0.14) or two-year mortality rate (OR = 0.84; 95% CI, 0.67 to 1.06; p=0.13) (N=2097). Although reporting of adverse effects was limited and inconsistent among trials (making pooling of data for this outcome impossible), adverse effects such as nausea/vomiting and hematologic toxic effects were consistently reported as being worse with combination chemotherapy across the eight eligible studies.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Compared to single-agent doxorubicin, the combination chemotherapy regimens evaluated, given in conventional doses, produced only marginal increases in response rates, at the expense of increased toxic effects and with no improvements in overall survival.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-08-07 14:07:18 +0100" MODIFIED_BY="Clare Jess">
<BACKGROUND>
<P>Soft tissue sarcomas are rare tumours of mesenchymal origin and represent approximately one per cent of all adult cancers. They may occur anywhere in the body but have a particular predilection for the limbs (including the buttock and shoulders) and the retroperitoneal space. Histological classification and grading of soft tissue sarcomas, which can be difficult and controversial, has changed over time with the incorporation of new histochemical markers. However, the classification schema outlined in the textbook by Enzinger and Weiss is widely accepted (<LINK REF="REF-Enzinger-1995" TYPE="REFERENCE">Enzinger 1995</LINK>). Histological groups described in European Organization for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group protocols for adult soft tissue sarcomas (as described below) will be used for this systematic review.</P>
<P>Doxorubicin was first identified as an active agent in the treatment of adult soft tissue sarcomas in the 1970s. Response rates in early studies ranged from 9 to 70% (<LINK REF="REF-Pinedo-1977" TYPE="REFERENCE">Pinedo 1977</LINK>). More recently, large randomized multicentre studies have established response rates in the range of 16 to 27% for single bolus doses of doxorubicin given every three weeks (<LINK REF="STD-Chang-1976" TYPE="STUDY">Chang 1976</LINK>; <LINK REF="STD-Schoenfeld-1982" TYPE="STUDY">Schoenfeld 1982</LINK>; <LINK REF="STD-Omura-1983" TYPE="STUDY">Omura 1983</LINK>; <LINK REF="STD-Muss-1985" TYPE="STUDY">Muss 1985</LINK>; <LINK REF="STD-Borden-1987" TYPE="STUDY">Borden 1987</LINK>; <LINK REF="STD-Borden-1990" TYPE="STUDY">Borden 1990</LINK>; <LINK REF="STD-Edmonson-1993" TYPE="STUDY">Edmonson 1993</LINK>; <LINK REF="STD-Santoro-1995" TYPE="STUDY">Santoro 1995</LINK>) . Subsequently, dacarbazine (DTIC) and ifosfamide (IFOS) were identified as active agents, with single-agent response rates of 18% (<LINK REF="REF-Buesa-1991" TYPE="REFERENCE">Buesa 1991</LINK>) and 18 to 36% (<LINK REF="REF-Stuart_x002d_Harris-1983" TYPE="REFERENCE">Stuart-Harris 1983</LINK>; <LINK REF="REF-Bramwell-1987" TYPE="REFERENCE">Bramwell 1987</LINK>; <LINK REF="REF-Antman-1989" TYPE="REFERENCE">Antman 1989</LINK>), respectively. A large number of other drugs have been evaluated, but these had minimal or inconsistent activity in patients with soft tissue sarcomas (<LINK REF="REF-Demetri-1995" TYPE="REFERENCE">Demetri 1995</LINK>).</P>
<P>Various combinations of the active drugs have been evaluated in a number of nonrandomized studies with documented response rates in the range of 35 to 60%, generally at the expense of greater toxicity (<LINK REF="REF-Bramwell-1991" TYPE="REFERENCE">Bramwell 1991</LINK>; <LINK REF="REF-Demetri-1995" TYPE="REFERENCE">Demetri 1995</LINK>). Combination chemotherapy regimens not containing doxorubicin have consistently yielded poor results in adult patients with advanced soft tissue sarcoma (<LINK REF="REF-Yap-1981" TYPE="REFERENCE">Yap 1981</LINK>; <LINK REF="STD-Schoenfeld-1982" TYPE="STUDY">Schoenfeld 1982</LINK>; <LINK REF="REF-Spielmann-1988" TYPE="REFERENCE">Spielmann 1988</LINK>). Results from large randomized studies comparing doxorubicin-based combination chemotherapy regimens with single-agent doxorubicin regimens have been more varied (<LINK REF="STD-Chang-1976" TYPE="STUDY">Chang 1976</LINK>; <LINK REF="STD-Schoenfeld-1982" TYPE="STUDY">Schoenfeld 1982</LINK>; <LINK REF="STD-Omura-1983" TYPE="STUDY">Omura 1983</LINK>; <LINK REF="STD-Muss-1985" TYPE="STUDY">Muss 1985</LINK>; <LINK REF="STD-Borden-1987" TYPE="STUDY">Borden 1987</LINK>; <LINK REF="STD-Borden-1990" TYPE="STUDY">Borden 1990</LINK>; <LINK REF="STD-Edmonson-1993" TYPE="STUDY">Edmonson 1993</LINK>; <LINK REF="STD-Santoro-1995" TYPE="STUDY">Santoro 1995</LINK>). In some of these trials, response rates have been higher in the combination chemotherapy arms, whereas in others, primary outcomes have not been significantly different between the treatments (<LINK REF="STD-Omura-1983" TYPE="STUDY">Omura 1983</LINK>; <LINK REF="STD-Borden-1990" TYPE="STUDY">Borden 1990</LINK>; <LINK REF="STD-Santoro-1995" TYPE="STUDY">Santoro 1995</LINK>).</P>
<P>Thus, there is considerable controversy as to whether any added benefit of combination chemotherapy outweighs increased toxic effects and inconvenience to patients, as well as the additional costs to health care systems. This has led to substantial variation in clinical practice. The Sarcoma Disease Site Group (DSG) felt that an unbiased, systematic review of the evidence was warranted.</P>
</BACKGROUND>
<OBJECTIVES>
<P>1. To determine if there is an advantage, in terms of response rate or survival, in using doxorubicin-based combination chemotherapy compared with single-agent doxorubicin for the palliative treatment of patients with incurable locally advanced or metastatic soft tissue sarcoma.</P>
<P>2. To determine if combination chemotherapy is associated with increased toxic effects compared with single-agent doxorubicin in this setting.</P>
<P>The use of adjuvant chemotherapy is not covered in this review, but has been the subject of an individual-patient-data meta-analysis (<LINK REF="REF-SMAC-1997" TYPE="REFERENCE">SMAC 1997</LINK>) and a separate systematic review and practice guideline developed by the Cancer Care Ontario Practice Guidelines Initiative (<LINK REF="REF-Figueredo-2000" TYPE="REFERENCE">Figueredo 2000</LINK>).</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>All randomized controlled trials that were published in English and compared single-agent doxorubicin with a doxorubicin-based combination chemotherapy regimen.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>At least 90% of trial participants met the following criteria:</P>
<P>1. Adult patients (i.e. older than 15 years of age) with locally advanced or metastatic soft tissue sarcoma who were candidates for palliative chemotherapy. </P>
<P>2. Eligible histological types including the following: alveolar soft part sarcoma, angiosarcoma / lymphangiosarcoma, fibrosarcoma, hemangiopericytoma, leiomyosarcoma, liposarcoma, malignant fibrous histiocytoma, neurogenic sarcoma, pleomorphic rhabdomyosarcoma, synovial sarcoma, unclassifiable sarcoma, undifferentiated sarcoma, miscellaneous sarcomas including uterine (mixed mesodermal, leiomyosarcoma and endometrial stromal sarcoma). </P>
<P>3. The following tumour types were excluded: bone sarcomas (e.g.., osteosarcoma, Ewing's sarcoma, chondrosarcoma), embryonal rhabdomyosarcoma, Kaposi sarcoma, malignant mesothelioma, neuroblastoma.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Doxorubicin alone versus any doxorubicin-based combination chemotherapy.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>1. Tumour response rate (complete and partial responses)<BR/>2. Progression-free survival (PFS)<BR/>3. Overall survival (OS)<BR/>4. Adverse effects<BR/>5. Quality of life</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>We originally searched MEDLINE (1966 through June 1999) and CANCERLIT (1975 through June 1999). We also searched EMBASE from 1979 to 1995 using the truncated keywords, "random" and "sarcoma" and scanned citation lists and personal files for additional studies. The Physician Data Query (PDQ) clinical trials database on the Internet (http://www.cancer.gov/search/clinical_trials/) and the American Society of Clinical Oncology (ASCO) Annual Meeting Proceedings (1995-1999) were also searched for additional reports of completed or ongoing trials. No further attempt was made to find reports of unpublished randomized controlled trials. Relevant articles and abstracts were selected and assessed by two reviewers (VB, DA), and the reference lists from these sources were searched for additional trials.</P>
<P>The original literature search has been updated using CENTRAL (The Cochrane Library issue 4, 2002), MEDLINE (through October 2002), CANCERLIT (through October 2002), and the proceedings of the annual meeting of the American Society of Clinical Oncology (ASCO) (2000 to 2002). </P>
<P>MEDLINE, CANCERLIT and CENTRAL were searched through Ovid, using the following search strategy:<BR/>001 random:.sh,tw,pt.<BR/>002 (double-blind method: or single-blind method:).sh,tw.<BR/>003 prospective: stud: .sh,tw.<BR/>004 multicent: stud: .sh,tw.<BR/>005 placebos/<BR/>006 or/1-5<BR/>007 (doxorubicin or adriamycin) .sh,tw.<BR/>008 combin: .tw.<BR/>009 7 and 8<BR/>010 exp sarcoma/<BR/>011 sarcoma:.mp.<BR/>012 (soft and tissue: and sarcoma:).mp.<BR/>013 or/10-12<BR/>014 9 and 13<BR/>015 14 and 6</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>Trial reports were assessed and data were abstracted by two reviewers (VB and DA). Studies were assessed for adherence to the following quality criteria: method of randomization, description of statistical methods and inclusion of sample size calculations.</P>
<P>Objective tumour response and mortality data from all eligible trials were pooled, in order to calculate overall estimates of treatment efficacy. The meta-analysis was based on data abstracted or estimated from the text, tables and figures in published papers. These data included the numbers of patients in each treatment group who experienced a complete or partial tumour response, died within one year of randomization, died within two years of randomization and were randomly allocated to the treatment. Death rates for single-agent and combination chemotherapy were compared at one year and two years after randomization. We used specific time points rather than other measures of survival, such as Hazard Ratios, because it was not possible to generate Kaplan Meier curves from the published data. In patients with inoperable locally advanced or metastatic soft tissue sarcoma, median overall survival is nine to twelve months. The early time point for survival analyses was chosen to be close to the expected median. By the second time point, at least 75% of deaths should have occurred. For trials with more than one doxorubicin-based single-agent or combination chemotherapy arm, data from all relevant groups in the trial were combined for the meta-analysis. Toxicity data were not combined, as the outcomes and measures varied greatly among studies. </P>
<P>For both response and death, the pooled result is expressed as an odds ratio (OR), which is the odds of an event occurring in the experimental group (combination chemotherapy) divided by the odds of an event occurring in the control group, (single-agent doxorubicin), and its 95% confidence interval (CI). For death, odds ratios greater than 1.0 favour single-agent therapy and estimates less than 1.0 favour combination therapy. For response, odds ratios less than 1.0 favour single-agent therapy and estimates greater than 1.0 favour combination therapy. Both the random effects and fixed effect model were considered. The results of the random effects model are reported in the text below, as the more conservative estimate of effect (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>). The Q-test was used to measure the quantitative heterogeneity among study results. </P>
<P>A sensitivity analysis was performed on trials that included a combination of doxorubicin with at least one other known active agent for soft tissue sarcoma (i.e. ifosfamide or DTIC) in their regimens.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-08-07 14:07:18 +0100" MODIFIED_BY="Clare Jess">
<STUDY_DESCRIPTION MODIFIED="2008-08-07 14:03:00 +0100" MODIFIED_BY="Clare Jess">
<P>Eight randomized controlled trials that compared doxorubicin combination chemotherapy with single-agent doxorubicin met the eligibility criteria (<LINK REF="STD-Chang-1976" TYPE="STUDY">Chang 1976</LINK>; <LINK REF="STD-Schoenfeld-1982" TYPE="STUDY">Schoenfeld 1982</LINK>; <LINK REF="STD-Omura-1983" TYPE="STUDY">Omura 1983</LINK>; <LINK REF="STD-Muss-1985" TYPE="STUDY">Muss 1985</LINK>; <LINK REF="STD-Borden-1987" TYPE="STUDY">Borden 1987</LINK>; <LINK REF="STD-Borden-1990" TYPE="STUDY">Borden 1990</LINK>; <LINK REF="STD-Edmonson-1993" TYPE="STUDY">Edmonson 1993</LINK>; <LINK REF="STD-Santoro-1995" TYPE="STUDY">Santoro 1995</LINK>) (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). No eligible studies were excluded from the systematic review. The trials ranged in size from 33 (<LINK REF="STD-Chang-1976" TYPE="STUDY">Chang 1976</LINK>) to 749 randomized patients (<LINK REF="STD-Santoro-1995" TYPE="STUDY">Santoro 1995</LINK>). In five studies central pathology review was performed for a majority of tumours (<LINK REF="STD-Omura-1983" TYPE="STUDY">Omura 1983</LINK>; <LINK REF="STD-Muss-1985" TYPE="STUDY">Muss 1985</LINK>; <LINK REF="STD-Borden-1987" TYPE="STUDY">Borden 1987</LINK>; <LINK REF="STD-Edmonson-1993" TYPE="STUDY">Edmonson 1993</LINK>). Some analysis of delivered dose of relevant drugs was performed in four studies (<LINK REF="STD-Muss-1985" TYPE="STUDY">Muss 1985</LINK>; <LINK REF="STD-Borden-1987" TYPE="STUDY">Borden 1987</LINK>; <LINK REF="STD-Edmonson-1993" TYPE="STUDY">Edmonson 1993</LINK>; <LINK REF="STD-Santoro-1995" TYPE="STUDY">Santoro 1995</LINK>).</P>
<P>Data on tumour response, survival, nausea and vomiting, and hematologic toxicity were reported for all eight trials. Two papers provided very limited data on adverse effects (<LINK REF="STD-Schoenfeld-1982" TYPE="STUDY">Schoenfeld 1982</LINK>; <LINK REF="STD-Omura-1983" TYPE="STUDY">Omura 1983</LINK>) , and only two papers provided detailed tabular reports of toxic effects seen in multiple systems (<LINK REF="STD-Borden-1990" TYPE="STUDY">Borden 1990</LINK>; <LINK REF="STD-Santoro-1995" TYPE="STUDY">Santoro 1995</LINK>). Because the number of patients randomized to each treatment group was not reported, the number of eligible patients was used for the meta-analysis for one trial (<LINK REF="STD-Santoro-1995" TYPE="STUDY">Santoro 1995</LINK>). Progression-free survival was not reported consistently across studies. Quality of life was not addressed in any of the studies included in this review.</P>
<P>There were nine single-agent doxorubicin arms (1086 total patients entered) in the eight studies. One study contributed data from two single-agent doxorubicin arms (<LINK REF="STD-Borden-1987" TYPE="STUDY">Borden 1987</LINK>). Each study included an arm in which high-dose single-agent doxorubicin was given every three weeks. In three studies the dose was 60 mg/m2 (<LINK REF="STD-Chang-1976" TYPE="STUDY">Chang 1976</LINK>; <LINK REF="STD-Omura-1983" TYPE="STUDY">Omura 1983</LINK>; <LINK REF="STD-Muss-1985" TYPE="STUDY">Muss 1985</LINK>), in another three studies, 70 mg/m2 (<LINK REF="STD-Schoenfeld-1982" TYPE="STUDY">Schoenfeld 1982</LINK>; <LINK REF="STD-Borden-1987" TYPE="STUDY">Borden 1987</LINK>; <LINK REF="STD-Borden-1990" TYPE="STUDY">Borden 1990</LINK>), and in one study each it was 75 mg/m2 (<LINK REF="STD-Santoro-1995" TYPE="STUDY">Santoro 1995</LINK>) and 80 mg/m2 (<LINK REF="STD-Edmonson-1993" TYPE="STUDY">Edmonson 1993</LINK>). In one study (<LINK REF="STD-Borden-1987" TYPE="STUDY">Borden 1987</LINK>), there was an additional arm in which doxorubicin (20 mg/m2 daily x 3) was administered as a loading dose followed by 15 mg/m2 weekly.</P>
<P>There were ten doxorubicin-based combination chemotherapy regimens given in eight studies (1195 total patients entered). The dose of doxorubicin in combination with other agents was 40 mg/m2 in one study (<LINK REF="STD-Edmonson-1993" TYPE="STUDY">Edmonson 1993</LINK>), 50 mg/m2 in two studies (<LINK REF="STD-Schoenfeld-1982" TYPE="STUDY">Schoenfeld 1982</LINK>; <LINK REF="STD-Santoro-1995" TYPE="STUDY">Santoro 1995</LINK>), 60 mg/m2 in five studies (<LINK REF="STD-Chang-1976" TYPE="STUDY">Chang 1976</LINK>; <LINK REF="STD-Omura-1983" TYPE="STUDY">Omura 1983</LINK>; <LINK REF="STD-Muss-1985" TYPE="STUDY">Muss 1985</LINK>; <LINK REF="STD-Borden-1987" TYPE="STUDY">Borden 1987</LINK>; <LINK REF="STD-Edmonson-1993" TYPE="STUDY">Edmonson 1993</LINK>), and 70 mg/m2 in one study (<LINK REF="STD-Borden-1990" TYPE="STUDY">Borden 1990</LINK>); in each case treatment was repeated every three weeks. The doxorubicin-based combination chemotherapy regimens included doxorubicin with vindesine (<LINK REF="STD-Borden-1990" TYPE="STUDY">Borden 1990</LINK>), streptozotocin (<LINK REF="STD-Chang-1976" TYPE="STUDY">Chang 1976</LINK>), cyclophosphamide (<LINK REF="STD-Muss-1985" TYPE="STUDY">Muss 1985</LINK>), ifosfamide (<LINK REF="STD-Edmonson-1993" TYPE="STUDY">Edmonson 1993</LINK>; <LINK REF="STD-Santoro-1995" TYPE="STUDY">Santoro 1995</LINK>), DTIC (<LINK REF="STD-Omura-1983" TYPE="STUDY">Omura 1983</LINK>; <LINK REF="STD-Borden-1987" TYPE="STUDY">Borden 1987</LINK>), mitomycin-C and cisplatin (<LINK REF="STD-Edmonson-1993" TYPE="STUDY">Edmonson 1993</LINK>), vincristine and cyclophosphamide (<LINK REF="STD-Schoenfeld-1982" TYPE="STUDY">Schoenfeld 1982</LINK>), and vincristine, cyclophosphamide and DTIC (<LINK REF="STD-Santoro-1995" TYPE="STUDY">Santoro 1995</LINK>).</P>
<P>Although a few patients who had received previous chemotherapy were included in the earlier studies (<LINK REF="STD-Chang-1976" TYPE="STUDY">Chang 1976</LINK>; <LINK REF="STD-Schoenfeld-1982" TYPE="STUDY">Schoenfeld 1982</LINK>; <LINK REF="STD-Omura-1983" TYPE="STUDY">Omura 1983</LINK>), most patients were chemotherapy-naive at study entry. Similarly, the majority had adult soft tissue sarcoma; although a few bone sarcomas and mesotheliomas were included in three studies (<LINK REF="STD-Chang-1976" TYPE="STUDY">Chang 1976</LINK>; <LINK REF="STD-Schoenfeld-1982" TYPE="STUDY">Schoenfeld 1982</LINK>; <LINK REF="STD-Edmonson-1993" TYPE="STUDY">Edmonson 1993</LINK>). All the trials excluded from their analysis some randomized patients who were subsequently found to be ineligible, as well as a variable number of patients who were not evaluable for survival and a larger number who were not evaluable for response.</P>
<P>No eligible ongoing trials were identified.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Only randomized trials were included in this systematic review. The trials were published between 1976 and 1995. In general, later reports included more details about study methods, particularly statistical analysis. Four studies described a satisfactory (central office) method of randomization (<LINK REF="STD-Schoenfeld-1982" TYPE="STUDY">Schoenfeld 1982</LINK>; <LINK REF="STD-Borden-1987" TYPE="STUDY">Borden 1987</LINK>; <LINK REF="STD-Borden-1990" TYPE="STUDY">Borden 1990</LINK>; <LINK REF="STD-Santoro-1995" TYPE="STUDY">Santoro 1995</LINK>), and four studies included an outline of the statistical methods employed for analysis (<LINK REF="STD-Omura-1983" TYPE="STUDY">Omura 1983</LINK>; <LINK REF="STD-Borden-1987" TYPE="STUDY">Borden 1987</LINK>; <LINK REF="STD-Borden-1990" TYPE="STUDY">Borden 1990</LINK>; <LINK REF="STD-Santoro-1995" TYPE="STUDY">Santoro 1995</LINK>). However, in only two papers were accrual goals set and met (<LINK REF="STD-Borden-1990" TYPE="STUDY">Borden 1990</LINK>; <LINK REF="STD-Santoro-1995" TYPE="STUDY">Santoro 1995</LINK>). The studies conducted by Chang et al and Muss et al were of inadequate size to properly evaluate differences in response rate or survival (<LINK REF="STD-Chang-1976" TYPE="STUDY">Chang 1976</LINK>; <LINK REF="STD-Muss-1985" TYPE="STUDY">Muss 1985</LINK>). Although response criteria were described or referenced in all except one study report (<LINK REF="STD-Schoenfeld-1982" TYPE="STUDY">Schoenfeld 1982</LINK>), it is generally accepted that the quality of evaluation of response has improved over the past 20 years because of better imaging techniques and attention to quality-control procedures. Thus, the results reported in later studies may be more reliable. </P>
<P>Overall, we did not feel that there were a sufficient number of trials in which the quality exceeded the remainder to justify a sensitivity analysis based on study quality. </P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-08-07 14:07:18 +0100" MODIFIED_BY="Clare Jess">
<SUBSECTION>
<HEADING LEVEL="3">Tumour response</HEADING>
<P>Response rates for single-agent doxorubicin ranged between 16% and 27% (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). Response rates for combination chemotherapy ranged from a low of 14% for doxorubicin and streptozotocin (<LINK REF="STD-Chang-1976" TYPE="STUDY">Chang 1976</LINK>) to 34% for doxorubicin and ifosfamide (<LINK REF="STD-Edmonson-1993" TYPE="STUDY">Edmonson 1993</LINK>). Response rates were significantly better for the combination chemotherapy regimens in only two trials. In one study (<LINK REF="STD-Borden-1987" TYPE="STUDY">Borden 1987</LINK>), the combination of doxorubicin and DTIC was superior to doxorubicin (p=0.03), given by two different schedules; in the second study (<LINK REF="STD-Edmonson-1993" TYPE="STUDY">Edmonson 1993</LINK>), the combination of doxorubicin and ifosfamide was superior to single-agent doxorubicin (p=0.03). In one study (<LINK REF="STD-Schoenfeld-1982" TYPE="STUDY">Schoenfeld 1982</LINK>), response rate was significantly better on doxorubicin compared with the combination of doxorubicin/vincristine/cyclophosphamide (p=0.03). Objective tumour response data were available for pooling from all eight trials, providing eight comparisons with a total of 2281 patients. There was no significant numerical heterogeneity among studies for objective tumour response (chi square = 9.45, p = 0.22). The pooled analysis for response (comparison 1.1) detected a difference favouring combination therapy with the fixed effect model (OR = 1.29; 95% CI, 1.03 to 1.60; p = 0.03) but not with the random effects model (OR = 1.26; 95% CI, 0.96 to 1.67; p = 0.10). When the meta-analysis was restricted to the four trials using combination regimens of known active agents (<LINK REF="STD-Omura-1983" TYPE="STUDY">Omura 1983</LINK>; <LINK REF="STD-Borden-1987" TYPE="STUDY">Borden 1987</LINK>; <LINK REF="STD-Edmonson-1993" TYPE="STUDY">Edmonson 1993</LINK>; <LINK REF="STD-Santoro-1995" TYPE="STUDY">Santoro 1995</LINK>), this difference was more pronounced (OR = 1.50; 95% CI, 1.16 to 1.95; p = 0.002 with both models).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Survival</HEADING>
<P>Median survival ranged from 7.7 to 12.0 months with single-agent doxorubicin ranged and 7.3 to 12.7 months with combination chemotherapy (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). None of the studies detected any significant differences in survival between single-agent doxorubicin and combination chemotherapy. Overall survival data for pooling were extracted directly from survival curves for six of the eight trials (<LINK REF="STD-Omura-1983" TYPE="STUDY">Omura 1983</LINK>; <LINK REF="STD-Muss-1985" TYPE="STUDY">Muss 1985</LINK>; <LINK REF="STD-Borden-1987" TYPE="STUDY">Borden 1987</LINK>; <LINK REF="STD-Borden-1990" TYPE="STUDY">Borden 1990</LINK>; <LINK REF="STD-Edmonson-1993" TYPE="STUDY">Edmonson 1993</LINK>; <LINK REF="STD-Santoro-1995" TYPE="STUDY">Santoro 1995</LINK>), with a total of 2097 patients. In two trials, survival data either were not reported (<LINK REF="STD-Chang-1976" TYPE="STUDY">Chang 1976</LINK>), or could not be extracted (<LINK REF="STD-Schoenfeld-1982" TYPE="STUDY">Schoenfeld 1982</LINK>). There was no significant numerical heterogeneity among studies for one-year (chi square = 0.67, p = 0.98) or two-year mortality (chi square = 3.42, p = 0.64). Pooled analysis of mortality data across six studies did not detect a statistically significant difference between single-agent and combination doxorubicin-based chemotherapy at one year (OR = 0.87; 95% CI, 0.73 to 1.05; p=0.14 with the random effects model) (comparison 1.2) or at two years (OR = 0.84; 95% CI, 0.67 to 1.05; p=0.13 with the random effects model) (comparison 1.3); results with the fixed effect model were almost identical (p = 0.13 at one year and 0.14 at two years). The conclusions of the meta-analysis did not significantly change when the data were restricted to the four trials using combinations of known active agents (<LINK REF="STD-Omura-1983" TYPE="STUDY">Omura 1983</LINK>; <LINK REF="STD-Borden-1987" TYPE="STUDY">Borden 1987</LINK>; <LINK REF="STD-Edmonson-1993" TYPE="STUDY">Edmonson 1993</LINK>; <LINK REF="STD-Santoro-1995" TYPE="STUDY">Santoro 1995</LINK>) (mortality OR = 0.89; 95% CI, 0.72 to 1.09; p = 0.3 at one year; OR, 0.90; 95% CI, 0.69 to 1.16; p = 0.4 at two years; with both models).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse effects</HEADING>
<P>Reporting of adverse effects was quite variable among the eight eligible trials, but all reported data on nausea/vomiting and hematological toxic effects (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). As all these studies were performed before the widespread use of 5HT3-antagonists, nausea and vomiting were reported frequently. With the exception of the study reported by Borden and colleagues (<LINK REF="STD-Borden-1990" TYPE="STUDY">Borden 1990</LINK>), rates of nausea and vomiting were always greater for combination regimens, often significantly so. Hematologic toxic effects were reported in different ways among studies. Sometimes leucopenia and thrombocytopenia were reported separately, sometimes in combination. In many of these studies, nadir blood counts were not necessarily performed and hematological toxicity may have been under-reported. As with nausea and vomiting, the rate of hematologic toxicity of combination chemotherapy was always higher than with single-agent doxorubicin. Neutropenic fever and other toxic effects, such as mucositis., were not reported consistently. Although the more recent studies did report toxic deaths (<LINK REF="STD-Muss-1985" TYPE="STUDY">Muss 1985</LINK>; <LINK REF="STD-Borden-1987" TYPE="STUDY">Borden 1987</LINK>; <LINK REF="STD-Borden-1990" TYPE="STUDY">Borden 1990</LINK>; <LINK REF="STD-Santoro-1995" TYPE="STUDY">Santoro 1995</LINK>), these were uncommon. Reporting of cardiotoxicity was highly variable and it was impossible to determine whether this was worse for single-agent or combination regimens; ultimately, it depended on the individual dose of doxorubicin received by each patient.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>Potential flaws of these studies include insufficient patient numbers for reliable statistical analysis and variability in pathological interpretation. A number of authors have suggested that response to chemotherapy may vary with histological subtype, but there are discrepancies between studies in identifying the most and least responsive histologies. The EORTC Soft Tissue and Bone Sarcoma Group has established the most extensive database that has been subjected to central histopathological review (<LINK REF="REF-van-Glabbeke-1999" TYPE="REFERENCE">van Glabbeke 1999</LINK>). Van Glabbeke et al reported on 2,185 patients with advanced STS treated in seven clinical trials investigating the use of anthracycline-containing regimens as first-line chemotherapy. Univariate analysis showed increased survival times for patients with liposarcoma and synovial sarcoma, decreased survival times for patients with malignant fibrous histiocytoma and a higher response rate for patients with liposarcoma (p&lt;0.05 for all log-rank and chi square tests). Multivariate analysis, however, identified a diagnosis of liposarcoma as the only favourable prognostic factor for response rate among the pathological subtypes (p=0.0065).</P>
<P>The main limitation of the present review is the fact that a number of different doxorubicin-based combination chemotherapy regimens have been compared with doxorubicin. Four of the eight studies compared combinations that included drugs considered to have limited activity as single-agent regimens in advanced soft tissue sarcoma (i.e. vincristine, vindesine, cyclophosphamide, streptozotocin, mitomycin-C, cisplatin). Even the four studies that used the known active agents in combination with doxorubicin (i.e. ifosfamide and DTIC) produced mixed results. Thus, the response rate for doxorubicin plus DTIC was better than that for doxorubicin alone in one study (<LINK REF="STD-Borden-1987" TYPE="STUDY">Borden 1987</LINK>) and similar in another study (<LINK REF="STD-Omura-1983" TYPE="STUDY">Omura 1983</LINK>). For doxorubicin plus ifosfamide, the response rate was better than for doxorubicin alone in the study reported by Edmonson and colleagues (<LINK REF="STD-Edmonson-1993" TYPE="STUDY">Edmonson 1993</LINK>), but similar in the EORTC study reported by Santoro and colleagues (<LINK REF="STD-Santoro-1995" TYPE="STUDY">Santoro 1995</LINK>). A meta-analysis of these four trials did detect a significant difference between single-agent doxorubicin and combination chemotherapy in terms of tumour response but not survival. The three-drug combination of doxorubicin, DTIC and ifosfamide (MAID) has never been directly compared with doxorubicin alone. However, a randomized study did detect a superior response rate with MAID compared with the combination of doxorubicin and DTIC (32% vs. 17%, p&lt;0.002) but with increased myelosuppression and no improvement in overall survival (<LINK REF="REF-Antman-1993" TYPE="REFERENCE">Antman 1993</LINK>). Since the publication of these studies, no new active drugs have been identified in soft tissue sarcoma.</P>
<P>In virtually all of the reviewed studies, the toxicity of combination chemotherapy (particularly nausea and vomiting, and myelosuppression) exceeded that of single-agent doxorubicin. It can be argued that modern anti-emetics and growth factor support might reduce or eliminate these differences, but in the setting of palliative chemotherapy, the costs of such strategies (particularly with granulocyte colony-stimulating factor [G-CSF]) must be weighed against the expected benefits.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Combinations of the known active drugs used at conventional doses can produce marginal increases in response rate in advanced metastatic soft tissue sarcoma, at the expense of increased adverse effects, but do not significantly increase survival rates. Thus, the results of this review favour the use of single-agent doxorubicin for palliative treatment of advanced/metastatic soft tissue sarcoma.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Future randomized clinical trials should compare new regimens, whose activity has been established in single-arm studies, with single agent doxorubicin. Future trials should include quality of life as an outcome measure.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2008-08-07 13:56:17 +0100" MODIFIED_BY="Clare Jess">
<P>*Robert Bell, Charles Catton, Jordi Cisa, Jane Curry, Aileen Davis, C. Jay Engel, Alvaro Figueredo, Victor Fornasier, Lorraine Hands, Brian O'Sullivan, Shailendra Verma, Rebecca Wong, Caroline Zwaal also contributed to the development of this systematic review. Please see the Cancer Care Ontario Practice Guidelines Initiative (CCOPGI) web site for a complete list of current Sarcoma Disease Site Group members: www.cancercare.on.ca/english/home/toolbox/qualityguidelines/diseasesite/sarcoma-ebs/sarcoma-dsg/</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>Members of the Sarcoma Disease Site Group were asked to disclose potential conflict of interest related to this systematic review. There was no known conflict of interest.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-08-07 13:53:09 +0100" MODIFIED_BY="Clare Jess">
<P>The primary reviewer is Vivien Bramwell.<BR/>Dale Anderson and Manya Charette also contributed to the development of the systematic review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2008-08-07 13:57:31 +0100" MODIFIED_BY="Clare Jess">
<P>This systematic review formed the basis for a clinical practice guideline developed by the Sarcoma Disease Site Group of the Cancer Care Ontario Practice Guidelines Initiative. It has been converted to a Cochrane review. It should be noted that for the purposes of the guidelines, the authors were requested to search only for studies published in English. The complete guideline report may be found on the web at: www.cancercare.on.ca/english/home/toolbox/qualityguidelines/diseasesite/sarcoma-ebs/sarcoma-dsg/</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Borden-1987" NAME="Borden 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Borden EC, Amato DA, Rosenbaum C, Enterline HT, Shiraki MJ, Creech RH, et al</AU>
<TI>Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1987</YR>
<VL>5</VL>
<PG>840-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Borden-1990" NAME="Borden 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Borden EC, Amato DA, Edmonson JH, Ritch PS, Shiraki M</AU>
<TI>Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft tissue sarcomas</TI>
<SO>Cancer</SO>
<YR>1990</YR>
<VL>66</VL>
<PG>862-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chang-1976" NAME="Chang 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chang P, Wiernik PH</AU>
<TI>Combination chemotherapy with adriamycin and streptozotocin. I. Clinical results in patients with advanced sarcoma</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1976</YR>
<VL>20</VL>
<PG>605-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Edmonson-1993" NAME="Edmonson 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Edmonson JH, Ryan LM, Blum RH, Brooks JSJ, Shiraki M, Frytak S, et al</AU>
<TI>Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1993</YR>
<VL>11</VL>
<PG>1269-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muss-1985" NAME="Muss 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muss MB, Bundy B, DiSaia J, Homesley HD, Fowler WC, Creasman W, et al</AU>
<TI>Treatment of recurrent or advanced uterine sarcoma: A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group)</TI>
<SO>Cancer</SO>
<YR>1985</YR>
<VL>55</VL>
<PG>1648-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Omura-1983" NAME="Omura 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Omura GA, Major FJ, Blessing JA, Sedlacek TV, Thigpen JT, Creasman WT, et al</AU>
<TI>A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas</TI>
<SO>Cancer</SO>
<YR>1983</YR>
<VL>52</VL>
<PG>626-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Santoro-1995" NAME="Santoro 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, et al</AU>
<TI>Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: A randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1995</YR>
<VL>13</VL>
<PG>1537-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schoenfeld-1982" NAME="Schoenfeld 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schoenfeld DA, Rosenbaum C, Horton J, Wolter JM, Falkson G, DeConti RC</AU>
<TI>A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-d and cyclophosphamide for advanced sarcoma</TI>
<SO>Cancer</SO>
<YR>1982</YR>
<VL>50</VL>
<PG>2757-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES/>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Antman-1989" NAME="Antman 1989" TYPE="JOURNAL_ARTICLE">
<AU>Antman KH, Ryan L, Elias A, Sherman D, Grier HE</AU>
<TI>Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1989</YR>
<VL>7</VL>
<PG>126-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Antman-1993" NAME="Antman 1993" TYPE="JOURNAL_ARTICLE">
<AU>Antman K, Crowley J, Balcerzak SP, Rivkin SE, Weiss GR, et al.</AU>
<TI>An Intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1993</YR>
<VL>11</VL>
<PG>1276-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bramwell-1987" NAME="Bramwell 1987" TYPE="JOURNAL_ARTICLE">
<AU>Bramwell VHC, Mouridsen HT, Santoro A, Blackledge G, Somers R, Verwey J, et al</AU>
<TI>Cyclophosphamide versus ifosfamide: Final report of a randomized phase II trial in adult soft tissue sarcomas</TI>
<SO>European Journal of Cancer &amp; Clinical Oncology</SO>
<YR>1987</YR>
<VL>23</VL>
<PG>311-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bramwell-1991" NAME="Bramwell 1991" TYPE="JOURNAL_ARTICLE">
<AU>Bramwell VH</AU>
<TI>Chemotherapy for metastatic soft tissue sarcomas - another full circle?</TI>
<SO>British Journal of Cancer</SO>
<YR>1991</YR>
<VL>64</VL>
<PG>7-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Buesa-1991" NAME="Buesa 1991" TYPE="JOURNAL_ARTICLE">
<AU>Buesa JM, Mouridsen HT, Van Oosterom AT, Verweij J, Wagener T, Steward W, et al</AU>
<TI>High dose DTIC in advanced soft tissue sarcomas in the adult. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group</TI>
<SO>Annals of Oncology</SO>
<YR>1991</YR>
<VL>2</VL>
<PG>307-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Demetri-1995" NAME="Demetri 1995" TYPE="JOURNAL_ARTICLE">
<AU>Demetri GD, Elias AD</AU>
<TI>Results of single agent and combination chemotherapy for advanced soft tissue sarcomas: implications for decision making in the clinic</TI>
<SO>Hematology/oncology clinics of North America</SO>
<YR>1995</YR>
<VL>9</VL>
<PG>765-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled clinical trials</SO>
<YR>1986</YR>
<VL>7</VL>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Enzinger-1995" NAME="Enzinger 1995" TYPE="BOOK">
<AU>Enzinger FM, Weiss SW</AU>
<SO>Soft Tissue Tumours</SO>
<YR>1995</YR>
<EN>Third</EN>
<PB>Mosby</PB>
<CY>St. Louis, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Figueredo-2000" NAME="Figueredo 2000" NOTES="&lt;p&gt;abstract available at: http://www.cancercare.on.ca/ccopgi/&lt;br&gt;full report to be submitted to Sarcoma&lt;/p&gt;" TYPE="UNPUBLISHED">
<AU>Figueredo A, Bramwell VHC, Bell R, Davis AM, Charette M and the members of the Cancer Care Ontario Practice Guidelines Initiative Sarcoma Disease Site Group</AU>
<TI>Adjuvant chemotherapy following complete resection of soft tissue sarcoma</TI>
<SO>Data on file</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pinedo-1977" NAME="Pinedo 1977" TYPE="JOURNAL_ARTICLE">
<AU>Pinedo HM, Kenis Y</AU>
<TI>Chemotherapy of advanced soft-tissue sarcomas in adults</TI>
<SO>Cancer treatment reviews</SO>
<YR>1977</YR>
<VL>4</VL>
<PG>67-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-SMAC-1997" NAME="SMAC 1997" TYPE="JOURNAL_ARTICLE">
<AU>Sarcoma Meta-analysis Collaboration</AU>
<TI>Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data</TI>
<SO>The Lancet</SO>
<YR>1997</YR>
<VL>350</VL>
<NO>9092</NO>
<PG>1647-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spielmann-1988" NAME="Spielmann 1988" TYPE="JOURNAL_ARTICLE">
<AU>Spielmann M, Sevin D, Le Chevalier T, Subirana R, Contesso G, Genin J, et al</AU>
<TI>Second line treatment in advanced sarcomas with vindesine (VDS) and cisplatin (DDP) by continuous infusion (CI) [abstract]</TI>
<SO>Proceedings of the American Society of Clinical Oncology</SO>
<YR>1988</YR>
<VL>7</VL>
<PG>276. Abstract 1072</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stuart_x002d_Harris-1983" NAME="Stuart-Harris 1983" TYPE="JOURNAL_ARTICLE">
<AU>Stuart-Harris RC, Harper PG, Parsons CA, Kaye SB, Mooney CA, Gowing NF, et al</AU>
<TI>High dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft tissue sarcoma</TI>
<SO>Cancer Chemotherapy &amp; Pharmacology</SO>
<YR>1983</YR>
<VL>11</VL>
<PG>69-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-Glabbeke-1999" NAME="van Glabbeke 1999" TYPE="JOURNAL_ARTICLE">
<AU>van Glabbeke M, van Oosterom A, Oosterhuis J, Mouridsen H, Crowther D, Somers R, et al</AU>
<TI>Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2,185 patients treated with anthracycline-containing first-line regimens - a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1999</YR>
<VL>17</VL>
<PG>150-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yap-1981" NAME="Yap 1981" TYPE="JOURNAL_ARTICLE">
<AU>Yap B-S, Benjamin RS, Burgess MA, Murphy WK, Sinkovics JG, Bodey GP</AU>
<TI>A phase II evaluation of methyl CCNU and actinomycin D in the treatment of advanced sarcomas in adults</TI>
<SO>Cancer</SO>
<YR>1981</YR>
<VL>47</VL>
<PG>2807-9</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES>
<REFERENCE ID="REF-Bramwell-2000" NAME="Bramwell 2000" TYPE="JOURNAL_ARTICLE">
<AU>Bramwell VHC, Anderson D, Charette ML</AU>
<TI>Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma: a meta-analysis and clinical practice guideline</TI>
<SO>Sarcoma</SO>
<YR>2000</YR>
<VL>4</VL>
<NO>3</NO>
<PG>103-12</PG>
<IDENTIFIERS/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Borden-1987">
<CHAR_METHODS>
<P>RCT<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>361 randomized<BR/>275 evaluable</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Dox q 3 weeks</P>
<P>Dox weekly</P>
<P>Dox + DTIC</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Response<BR/>Survival<BR/>Toxicity<BR/>PFI<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Two single-agent doxorubicin arms included</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Borden-1990">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>347 randomized<BR/>298 evaluable</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Dox</P>
<P>Dox + vindesine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Response<BR/>Survival<BR/>Toxicity<BR/>PFI</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Chang-1976">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>33 randomized<BR/>31 evaluable</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Dox</P>
<P>Dox + streptozotozin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Response<BR/>Survival<BR/>Toxicity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Edmonson-1993">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>279 randomized<BR/>262 evaluable</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Dox</P>
<P>Dox + ifosfomide</P>
<P>Dox + mitomycin + CDDP</P>
<P/>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Response<BR/>Survival<BR/>Toxicity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Two dox-based combination arms included</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Muss-1985">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>132 randomized<BR/>104 evaluable<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Dox</P>
<P>Dox + cyclo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Response<BR/>Survival<BR/>Toxicity<BR/>PFI</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Omura-1983">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>315 randomized<BR/>226 evaluable</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Dox</P>
<P>Dox + DTIC</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Response<BR/>Survival<BR/>Toxicity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Santoro-1995">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>749 randomized<BR/>663 evaluable</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Dox</P>
<P>Dox + ifosfamide</P>
<P>CYVADIC</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Response <BR/>Survival<BR/>Toxicity<BR/>PFI</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Two dox-based combination arms included</P>
<P>CYVADIC arm closed early</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Schoenfeld-1982">
<CHAR_METHODS>
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>151 randomized<BR/>136 evaluable<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Dox</P>
<P>Dox + cyclo + vincristine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Response<BR/>Survival<BR/>Toxicity<BR/>PFI</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Third arm not included - did not contain dox</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>CDDP, cisplatin; cyclo, cyclophosphamide; CYVADIC, cyclophosphamide/vincristine/doxorubicin/dacarbazine; dox, doxorubicin; DTIC, dacarbazine; PFI, progression-free interval; RTC, randomized controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Borden-1987">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Borden-1990">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Chang-1976">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Edmonson-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Muss-1985">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Omura-1983">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Santoro-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Schoenfeld-1982">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES>
<ADDITIONAL_TABLE ID="TBL-01" NO="1">
<TITLE>RCTs - Doxorubicin combination chemotherapy</TITLE>
<TABLE COLS="5" ROWS="28">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Tumour type</P>
</TH>
<TH>
<P>Chemotherapy</P>
</TH>
<TH>
<P>Regimens*</P>
</TH>
<TH>
<P>Evaluable Patients</P>
</TH>
</TR>
<TR>
<TD>
<P>Chang &amp; Wiernik,<BR/>1976 (4)<BR/>NCI (US)<BR/>
</P>
</TD>
<TD>
<P>Adult STS<BR/>(4 bone sarcomas)<BR/>4 prior chemo</P>
</TD>
<TD>
<P>DOX<BR/>
<BR/> DOX<BR/>STREPT<BR/>
<BR/>
<BR/>
</P>
</TD>
<TD>
<P>60 mg/m2 IV bolus<BR/>
<BR/>60 mg/m2 IV bolus<BR/>500 mg/m2 IV bolus d1-5<BR/>
</P>
</TD>
<TD>
<P>18 (17)<BR/>
<BR/>15 (14)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Schoenfeld et al, 1982 (5) &#8224;<BR/>ECOG<BR/>
</P>
</TD>
<TD>
<P>Adult STS<BR/>(18 bone sarcomas,<BR/> 9 mesotheliomas)<BR/>3 prior chemo<BR/>
</P>
</TD>
<TD>
<P>DOX<BR/>
<BR/> DOX<BR/>VCR<BR/>CYCLO<BR/>
</P>
</TD>
<TD>
<P>70 mg/m2 IV bolus<BR/>
<BR/>50 mg/m2 IV bolus<BR/>1.4 mg/m2 IV bolus<BR/>750 mg/m2 IV bolus<BR/>
</P>
</TD>
<TD>
<P>71 (66)<BR/>
<BR/>80 (70)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Omura et al,<BR/>1983 (6)<BR/>GOG<BR/>
</P>
</TD>
<TD>
<P>Uterine sarcomas<BR/>
<BR/>31 prior chemo<BR/>
</P>
</TD>
<TD>
<P>DOX<BR/>
<BR/> DOX<BR/>DTIC<BR/>
</P>
</TD>
<TD>
<P>60 mg/m2 IV bolus<BR/>
<BR/>60 mg/m2 IV bolus<BR/>250 mg/m2 IV bolus d1-5<BR/>
</P>
</TD>
<TD>
<P>155 (120)<BR/>
<BR/>160 (106)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Muss et al,<BR/>1985 (7)<BR/>GOG<BR/>
</P>
</TD>
<TD>
<P>Uterine sarcomas</P>
</TD>
<TD>
<P>DOX<BR/>
<BR/> DOX<BR/>CYCLO<BR/>
</P>
</TD>
<TD>
<P>60 mg/m2 IV bolus<BR/>
<BR/>60 mg/m2 IV bolus<BR/>500 mg/m2 IV bolus<BR/>
</P>
</TD>
<TD>
<P>66 (50)<BR/>
<BR/>66 (54)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Borden et al,<BR/>1987 (8)<BR/>ECOG<BR/>
</P>
</TD>
<TD>
<P>Adult STS</P>
</TD>
<TD>
<P>DOX<BR/>
<BR/> DOX<BR/>
<BR/> DOX<BR/>DTIC<BR/>
</P>
</TD>
<TD>
<P>70 mg/m2 IV bolus<BR/>
<BR/>20 mg/m2 d1,2,3 IV bolus, then 15 mg/m2/wk<BR/>
<BR/>60 mg/m2 IV bolus<BR/>250 mg/m2 IV bolus d1-5<BR/>
</P>
</TD>
<TD>
<P>123 (94)<BR/>
<BR/>119 (88)<BR/>
<BR/>119 (92)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Borden et al,<BR/>1990 (9)<BR/>ECOG<BR/>
</P>
</TD>
<TD>
<P>Adult STS</P>
</TD>
<TD>
<P>DOX<BR/>
<BR/> DOX<BR/>VND<BR/>
</P>
</TD>
<TD>
<P>70 mg/m2 IV bolus<BR/>
<BR/>70 mg/m2 IV bolus<BR/>3 mg/m2 IV bolus<BR/>
</P>
</TD>
<TD>
<P>176 (151)<BR/>
<BR/>171 (147)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Edmonson et al, 1993 (10)<BR/>ECOG<BR/>
</P>
</TD>
<TD>
<P>Adult STS<BR/>
<BR/>(4 bone sarcomas)<BR/>
</P>
</TD>
<TD>
<P>DOX<BR/>
<BR/> DOX<BR/>IFOS<BR/>
<BR/> DOX<BR/>MITC<BR/>DDP<BR/>
</P>
</TD>
<TD>
<P>80 mg/m2 IV bolus<BR/>
<BR/>60 mg/m2 IV bolus<BR/>3.75 g/m2 IV 4 hrs x 2 days<BR/>
<BR/>40 mg/m2 IV bolus<BR/>8 mg/m2 IV bolus<BR/>60 mg/m2 IV bolus<BR/>
</P>
</TD>
<TD>
<P>95 (90)<BR/>
<BR/>94 (88)<BR/>
<BR/>
<BR/>90 (84)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Santoro et al,1995 (11)EORTC</P>
</TD>
<TD>
<P>Adult STS</P>
</TD>
<TD>
<P>DOX<BR/>
<BR/> DOX<BR/>VCR<BR/>CYCLO<BR/>DTIC<BR/>
<BR/> DOX<BR/>IFOS<BR/>
</P>
</TD>
<TD>
<P>75 mg/m2 IV bolus<BR/>
<BR/>50 mg/m2 IV bolus<BR/>1.5 mg/m2 IV bolus<BR/>500 mg/m2 IV bolus<BR/>750 mg/m2 IV 30 mins<BR/>
<BR/>50 mg/m2 IV bolus<BR/>5 g/m2 CIV 24 hrs<BR/>
</P>
</TD>
<TD>
<P>263 (240)<BR/>
<BR/>142 (134)<BR/>
<BR/>
<BR/>
<BR/>
<BR/>258 (231)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Footnote:</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>CYCLO = cyclophosphamide</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>DDP = cisplatin</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>DOX = doxorubicin (Adriamycin)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>DTIC = dacarbazine</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>ECOG = Eastern Cooperative Oncology Group</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>EORTC = European Organization for Research and Treatment of Cancer</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>GOG = Gynecologic Oncology Group</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>IFOS = ifosfamide</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>MITC = mitomycin</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>NCI = National Cancer Institute</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>STREPT = streptozotocin</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>STS = soft tissue sarcoma</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>VCR = vincristine</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>VND = vindesine<BR/>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>* all doses given every three weeks, unless otherwise stated<BR/>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>&#8224; third arm: vincristine, Actinomycin D, cyclophosphamide.<BR/>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" NO="2">
<TITLE>Response rates and median survival times</TITLE>
<TABLE COLS="5" ROWS="23">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Evaluable patients</P>
</TH>
<TH>
<P>Responders</P>
</TH>
<TH>
<P>Med. surv. (months)</P>
</TH>
</TR>
<TR>
<TD>
<P>Chang &amp; Wiernick,<BR/>1976 (4)<BR/>
</P>
</TD>
<TD>
<P>DOX<BR/>
<BR/>DOX/STREPT<BR/>
</P>
</TD>
<TD>
<P>17<BR/>
<BR/>14<BR/>
</P>
</TD>
<TD>
<P>4 (24)<BR/>
<BR/>2 (14)<BR/>p=NS<BR/>
</P>
</TD>
<TD>
<P>10.2<BR/>
<BR/>10.6<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Schoenfeld et al,<BR/>1982 (5)<BR/>
</P>
</TD>
<TD>
<P>DOX<BR/>
<BR/>DOX/VCR/CYCLO<BR/>
</P>
</TD>
<TD>
<P>66<BR/>
<BR/>70<BR/>
</P>
</TD>
<TD>
<P>18 (27)<BR/>
<BR/>13 (19)<BR/>p=0.03*<BR/>
</P>
</TD>
<TD>
<P>8.5<BR/>
<BR/>7.8<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Omura et al,<BR/>1983 (6)<BR/>
</P>
</TD>
<TD>
<P>DOX<BR/>
<BR/>DOX/DTIC<BR/>
</P>
</TD>
<TD>
<P>120<BR/>
<BR/>106<BR/>
</P>
</TD>
<TD>
<P>13/80 (16)<BR/>
<BR/>16/66 (24)<BR/>p=NS<BR/>
</P>
</TD>
<TD>
<P>7.7<BR/>
<BR/>7.3<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Muss et al,<BR/>1985 (7)<BR/>
</P>
</TD>
<TD>
<P>DOX<BR/>
<BR/>DOX/CYCLO<BR/>
</P>
</TD>
<TD>
<P>50<BR/>
<BR/>54<BR/>
</P>
</TD>
<TD>
<P>5/26 (19)<BR/>
<BR/>5/26 (19)<BR/>p=NS<BR/>
</P>
</TD>
<TD>
<P>11.6<BR/>
<BR/>10.9<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Borden et al,<BR/>1987 (8)<BR/>
</P>
</TD>
<TD>
<P>DOX q 3 wk<BR/>
<BR/>DOX loading then weekly<BR/>
<BR/>DOX/DTIC<BR/>
</P>
</TD>
<TD>
<P>94<BR/>
<BR/>88<BR/>
<BR/>92<BR/>
</P>
</TD>
<TD>
<P>17 (18)<BR/>
<BR/>15 (17)<BR/>
<BR/>28 (30)<BR/>p=0.03&#8224;<BR/>
</P>
</TD>
<TD>
<P>8.0<BR/>
<BR/>8.4<BR/>
<BR/>8.0<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Borden et al,<BR/>1990 (9)<BR/>
</P>
</TD>
<TD>
<P>DOX<BR/>
<BR/>DOX/VND<BR/>
</P>
</TD>
<TD>
<P>151<BR/>
<BR/>147<BR/>
</P>
</TD>
<TD>
<P>26 (17)<BR/>
<BR/>26 (18)<BR/>p=NS<BR/>
</P>
</TD>
<TD>
<P>9.4<BR/>
<BR/>9.9<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Edmonson et al,<BR/>1993 (10)<BR/>
</P>
</TD>
<TD>
<P>DOX<BR/>
<BR/>DOX/IFOS<BR/>
<BR/>DOX/MITC/DDP<BR/>
</P>
</TD>
<TD>
<P>90<BR/>
<BR/>88<BR/>
<BR/>84<BR/>
</P>
</TD>
<TD>
<P>18 (20)<BR/>
<BR/>30 (34)<BR/>
<BR/>27 (32)<BR/>p=0.03&#8224;<BR/>
</P>
</TD>
<TD>
<P>8.4<BR/>
<BR/>11.5<BR/>
<BR/>9.4<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Santoro et al,<BR/>1995 (11)<BR/>
</P>
</TD>
<TD>
<P>DOX<BR/>
<BR/>DOX/VCR/CYCLO/DTIC<BR/>
<BR/>DOX/IFOS<BR/>
</P>
</TD>
<TD>
<P>240<BR/>
<BR/>134<BR/>
<BR/>231<BR/>
</P>
</TD>
<TD>
<P>56 (23)<BR/>
<BR/>38 (28)<BR/>
<BR/>65 (28)<BR/>p=NS<BR/>
</P>
</TD>
<TD>
<P>12.0<BR/>
<BR/>11.8<BR/>
<BR/>12.7<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Footnote:</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>CYCLO = cyclophosphamide</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>DDP = cisplatin</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>DOX = doxorubicin (Adriamycin)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>DTIC = dacarbazine</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>IFOS = ifosfamide</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>MITC = mitomycin</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>NS = not significant</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>STREPT = streptozotocin</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>VCR = vincristine</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>VND = vindesine</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>* Single-agent doxorubicin better than combination chemotherapy<BR/>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>&#8224; Doxorubicin combination chemotherapy better than single-agent doxorubicin.<BR/>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" NO="3">
<TITLE>Toxic effects</TITLE>
<TABLE COLS="6" ROWS="22">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Nausea &amp; vomiting</P>
</TH>
<TH>
<P>WBC</P>
</TH>
<TH>
<P>Platelet count</P>
</TH>
<TH>
<P>Haematologic</P>
</TH>
</TR>
<TR>
<TD>
<P>Chang &amp; Wiernick,<BR/>1976 (4)<BR/>
</P>
</TD>
<TD>
<P>DOX<BR/>
<BR/>DOX + STREPT<BR/>
</P>
</TD>
<TD>
<P>59% mild/mod<BR/>
<BR/>100% mod/severe<BR/>
</P>
</TD>
<TD>
<P>WBC &lt;2000<BR/>9%<BR/>
<BR/>30% (p&lt;0.01)<BR/>
</P>
</TD>
<TD>
<P>PLATS &lt;100,000<BR/>3%<BR/>
<BR/>13% (p&lt;0.03)<BR/>
</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Schoenfeld et al,<BR/>1982 (5)<BR/>
</P>
</TD>
<TD>
<P>DOX<BR/>
<BR/>DOX/VCR/CYCLO<BR/>
</P>
</TD>
<TD>
<P>42% mod/severe<BR/>
<BR/>60% mod/severe<BR/>(p=0.09)<BR/>
</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>17% severe<BR/>
<BR/>30% severe<BR/>(p=0.07)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Omura et al,<BR/>1983 (6)<BR/>
</P>
</TD>
<TD>
<P>DOX<BR/>
<BR/>DOX/DTIC<BR/>
</P>
</TD>
<TD>
<P>Grade 3/4<BR/>2.2%<BR/>
<BR/>8.5%<BR/>
</P>
</TD>
<TD>
<P>Grade 3/4<BR/>16%<BR/>
<BR/>35%<BR/>
</P>
</TD>
<TD>
<P>Grade 3/4<BR/>4%<BR/>
<BR/>13%<BR/>
</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Muss et al,<BR/>1985 (7)<BR/>
</P>
</TD>
<TD>
<P>DOX<BR/>
<BR/>DOX/CYCLO<BR/>
</P>
</TD>
<TD>
<P>0% severe<BR/>
<BR/>6% severe<BR/>
</P>
</TD>
<TD>
<P>WBC &lt;2000<BR/>10%<BR/>
<BR/>35%<BR/>
</P>
</TD>
<TD>
<P>PLATS&lt;50,000<BR/>0%<BR/>
<BR/>0%<BR/>
</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Borden et al,<BR/>1987 (8)<BR/>
</P>
</TD>
<TD>
<P>DOX q 3 wk<BR/>
<BR/>DOX loading q/wk<BR/>
<BR/>DOX/DTIC<BR/>
</P>
</TD>
<TD>
<P>11% severe<BR/>
<BR/>6% severe<BR/>
<BR/>29% severe<BR/>(p=0.00003)<BR/>
</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>28% severe<BR/>
<BR/>13% severe<BR/>
<BR/>29% severe<BR/>(p=0.87)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Borden et al,<BR/>1990 (9)<BR/>
</P>
</TD>
<TD>
<P>DOX<BR/>
<BR/>DOX/VND<BR/>
</P>
</TD>
<TD>
<P>6% severe<BR/>
<BR/>3% severe<BR/>
</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>36% severe<BR/>
<BR/>50% severe<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Edmonson et al,<BR/>1993 (10)<BR/>
</P>
</TD>
<TD>
<P>DOX<BR/>
<BR/>DOX/IFOS<BR/>
<BR/>DOX/MITC/DDP<BR/>
</P>
</TD>
<TD>
<P>7% severe<BR/>
<BR/>18% severe<BR/>
<BR/>17% severe<BR/>
</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>53% 80% 55% (p=0.01)</P>
</TD>
</TR>
<TR>
<TD>
<P>Santoro et al,<BR/>1995 (11)<BR/>
</P>
</TD>
<TD>
<P>DOX<BR/>
<BR/>DOX/VCR/CYCLO/DTIC<BR/>
<BR/>DOX/IFOS<BR/>
</P>
</TD>
<TD>
<P>Grade 3/4<BR/>17%<BR/>
<BR/>40%<BR/>
<BR/>NR<BR/>
</P>
</TD>
<TD>
<P>Grade 4<BR/>13%<BR/>
<BR/>15%<BR/>
<BR/>32%<BR/>(p&lt;0.001)<BR/>
</P>
</TD>
<TD>
<P>Grade 3/4<BR/>4%<BR/>
<BR/>10%<BR/>
<BR/>6%<BR/>
</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Footnote:</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>DOX=doxorubicin (Adriamycin)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>STREPT=streptozotocin</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>VCR=vincristine</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>CYCLO=cyclophosphamide</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>DTIC=dacarbazine</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>VND=vindesine</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>WBC = white blood cell</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>IFOS=ifosfamide</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>MITC=mitomycin</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>DDP=cisplatin</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>NR = not reported</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Single-agent doxorubicin vs. doxorubicin-based combination chemotherapy</NAME>
<DICH_OUTCOME CHI2="9.45024677609952" CI_END="1.6665847249069172" CI_START="0.956046354705623" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.262272653215355" ESTIMABLE="YES" EVENTS_1="249" EVENTS_2="172" I2="25.92786023637397" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.2218273969789923" LOG_CI_START="-0.01952105008288956" LOG_EFFECT_SIZE="0.10115317344805137" METHOD="MH" NO="1" P_CHI2="0.221925285575017" P_Q="0.0" P_Z="0.1004020902102646" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.03977322305691389" TOTALS="YES" TOTAL_1="1195" TOTAL_2="1086" WEIGHT="99.99999999999997" Z="1.6429074170034406">
<NAME>Objective tumour response (complete or partial)</NAME>
<GROUP_LABEL_1>Combination</GROUP_LABEL_1>
<GROUP_LABEL_2>Single-agent</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single-agent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.5480820334705885" CI_START="1.1491540671679576" EFFECT_SIZE="2.019230769230769" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="32" LOG_CI_END="0.5499936523862252" LOG_CI_START="0.06037825848405266" LOG_EFFECT_SIZE="0.3051859554351389" ORDER="40" O_E="0.0" SE="0.2876025060134238" STUDY_ID="STD-Borden-1987" TOTAL_1="119" TOTAL_2="242" VAR="0.08271520146520146" WEIGHT="16.408511010808724"/>
<DICH_DATA CI_END="1.8654030502682983" CI_START="0.5736854444027811" EFFECT_SIZE="1.0344827586206897" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="26" LOG_CI_END="0.27077268257672676" LOG_CI_START="-0.24132616893531397" LOG_EFFECT_SIZE="0.014723256820706378" ORDER="41" O_E="0.0" SE="0.30080940030837056" STUDY_ID="STD-Borden-1990" TOTAL_1="171" TOTAL_2="176" VAR="0.09048629531388153" WEIGHT="15.429603054008819"/>
<DICH_DATA CI_END="3.4509252191298936" CI_START="0.0840182878478809" EFFECT_SIZE="0.5384615384615384" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.5379355483175312" LOG_CI_START="-1.075626172902691" LOG_EFFECT_SIZE="-0.26884531229257996" ORDER="42" O_E="0.0" SE="0.9478141423040956" STUDY_ID="STD-Chang-1976" TOTAL_1="15" TOTAL_2="18" VAR="0.8983516483516483" WEIGHT="2.1424148572567083"/>
<DICH_DATA CI_END="3.4155775109058526" CI_START="1.025482868361225" EFFECT_SIZE="1.8715277777777777" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="18" LOG_CI_END="0.5334641453805995" LOG_CI_START="0.010928409474416164" LOG_EFFECT_SIZE="0.2721962774275078" ORDER="43" O_E="0.0" SE="0.30694007786490085" STUDY_ID="STD-Edmonson-1993" TOTAL_1="184" TOTAL_2="95" VAR="0.09421221139971139" WEIGHT="15.000530995168633"/>
<DICH_DATA CI_END="3.630580278221948" CI_START="0.27543806316541314" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5599760441791122" LOG_CI_START="-0.5599760441791122" LOG_EFFECT_SIZE="0.0" ORDER="44" O_E="0.0" SE="0.6578654005538684" STUDY_ID="STD-Muss-1985" TOTAL_1="66" TOTAL_2="66" VAR="0.4327868852459017" WEIGHT="4.253115375493848"/>
<DICH_DATA CI_END="2.615154532869238" CI_START="0.5632583106564848" EFFECT_SIZE="1.2136752136752136" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" LOG_CI_END="0.41749735698511076" LOG_CI_START="-0.24929239171132106" LOG_EFFECT_SIZE="0.08410248263689481" ORDER="45" O_E="0.0" SE="0.3916755990467725" STUDY_ID="STD-Omura-1983" TOTAL_1="160" TOTAL_2="155" VAR="0.15340977488864813" WEIGHT="10.403879657329416"/>
<DICH_DATA CI_END="1.857105347343514" CI_START="0.8848907333802833" EFFECT_SIZE="1.281926406926407" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="56" LOG_CI_END="0.26883654050460254" LOG_CI_START="-0.05311035282724814" LOG_EFFECT_SIZE="0.10786309383867719" ORDER="46" O_E="0.0" SE="0.18911319880595334" STUDY_ID="STD-Santoro-1995" TOTAL_1="400" TOTAL_2="263" VAR="0.03576380196262003" WEIGHT="26.607516803157047"/>
<DICH_DATA CI_END="1.2704621481735052" CI_START="0.2569106440610716" EFFECT_SIZE="0.5713101160862355" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="18" LOG_CI_END="0.10396173031967307" LOG_CI_START="-0.5902179021126865" LOG_EFFECT_SIZE="-0.2431280858965067" ORDER="47" O_E="0.0" SE="0.40776455233536757" STUDY_ID="STD-Schoenfeld-1982" TOTAL_1="80" TOTAL_2="71" VAR="0.16627193014126274" WEIGHT="9.75442824677678"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6677670173299551" CI_END="1.04608370654936" CI_START="0.7315007970292304" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8747634337923302" ESTIMABLE="YES" EVENTS_1="600" EVENTS_2="595" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.019566437722432065" LOG_CI_START="-0.1357851963394795" LOG_EFFECT_SIZE="-0.058109379308523695" METHOD="MH" NO="2" P_CHI2="0.98469076690926" P_Q="0.0" P_Z="0.14257975720175903" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1100" TOTAL_2="997" WEIGHT="99.99999999999999" Z="1.4662515949242545">
<NAME>Death at one year</NAME>
<GROUP_LABEL_1>Combination</GROUP_LABEL_1>
<GROUP_LABEL_2>Single-agent</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours combination</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours single-agent</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3826159700616802" CI_START="0.5509835709067128" EFFECT_SIZE="0.8728107952914155" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="162" LOG_CI_END="0.14070156894277458" LOG_CI_START="-0.25886135064173954" LOG_EFFECT_SIZE="-0.05907989084948251" ORDER="48" O_E="0.0" SE="0.23470523683229422" STUDY_ID="STD-Borden-1987" TOTAL_1="119" TOTAL_2="242" VAR="0.05508654819650331" WEIGHT="15.037973487145562"/>
<DICH_DATA CI_END="1.1775359911248098" CI_START="0.5022635148118735" EFFECT_SIZE="0.769047050394077" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="106" LOG_CI_END="0.07097419011772767" LOG_CI_START="-0.2990683685085267" LOG_EFFECT_SIZE="-0.11404708919539953" ORDER="49" O_E="0.0" SE="0.21736483067726894" STUDY_ID="STD-Borden-1990" TOTAL_1="171" TOTAL_2="176" VAR="0.04724746961535779" WEIGHT="18.806870250508585"/>
<DICH_DATA CI_END="1.402155480525044" CI_START="0.5125375867513944" EFFECT_SIZE="0.8477366255144033" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="57" LOG_CI_END="0.14679617382333116" LOG_CI_START="-0.2902742802816486" LOG_EFFECT_SIZE="-0.07173905322915877" ORDER="50" O_E="0.0" SE="0.25673734827490596" STUDY_ID="STD-Edmonson-1993" TOTAL_1="184" TOTAL_2="95" VAR="0.06591406599923036" WEIGHT="12.896406620196474"/>
<DICH_DATA CI_END="1.9791854879808792" CI_START="0.5052583530309621" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="34" LOG_CI_END="0.29648649791109066" LOG_CI_START="-0.2964864979110906" LOG_EFFECT_SIZE="0.0" ORDER="51" O_E="0.0" SE="0.34831527300961795" STUDY_ID="STD-Muss-1985" TOTAL_1="66" TOTAL_2="66" VAR="0.1213235294117647" WEIGHT="6.42344501278851"/>
<DICH_DATA CI_END="1.3726685352051917" CI_START="0.539411833715851" EFFECT_SIZE="0.860484544695071" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="105" LOG_CI_END="0.13756567874405362" LOG_CI_START="-0.2680795301465305" LOG_EFFECT_SIZE="-0.06525692570123848" ORDER="52" O_E="0.0" SE="0.23827800367849739" STUDY_ID="STD-Omura-1983" TOTAL_1="160" TOTAL_2="155" VAR="0.05677640703701001" WEIGHT="14.806985378744102"/>
<DICH_DATA CI_END="1.2697920059137295" CI_START="0.6813158148182594" EFFECT_SIZE="0.9301233118027011" ESTIMABLE="YES" EVENTS_1="192" EVENTS_2="131" LOG_CI_END="0.10373258860816824" LOG_CI_START="-0.1666515300264209" LOG_EFFECT_SIZE="-0.03145947070912632" ORDER="53" O_E="0.0" SE="0.1588249697089307" STUDY_ID="STD-Santoro-1995" TOTAL_1="400" TOTAL_2="263" VAR="0.025225371003042757" WEIGHT="32.02831925061676"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.4190873181220622" CI_END="1.0520276838344909" CI_START="0.6713241501559987" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8403877621614758" ESTIMABLE="YES" EVENTS_1="873" EVENTS_2="822" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.022027168314265592" LOG_CI_START="-0.1730677292625206" LOG_EFFECT_SIZE="-0.0755202804741275" METHOD="MH" NO="3" P_CHI2="0.6356646326889994" P_Q="0.0" P_Z="0.12916952370494403" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1100" TOTAL_2="997" WEIGHT="100.0" Z="1.5173849410735742">
<NAME>Death at two years</NAME>
<GROUP_LABEL_1>Combination</GROUP_LABEL_1>
<GROUP_LABEL_2>Single-agent</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours combination</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours single-agent</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9992287369292012" CI_START="0.6110389599920537" EFFECT_SIZE="1.105263157894737" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="200" LOG_CI_END="0.30086248571547375" LOG_CI_START="-0.21393109815329303" LOG_EFFECT_SIZE="0.043465693781090345" ORDER="54" O_E="0.0" SE="0.3023922994338517" STUDY_ID="STD-Borden-1987" TOTAL_1="119" TOTAL_2="242" VAR="0.09144110275689223" WEIGHT="12.618147093862515"/>
<DICH_DATA CI_END="1.1297761929383139" CI_START="0.36633248493751747" EFFECT_SIZE="0.6433301797540208" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="151" LOG_CI_END="0.052992418882821836" LOG_CI_START="-0.4361245680852018" LOG_EFFECT_SIZE="-0.19156607460118993" ORDER="55" O_E="0.0" SE="0.28730973931315057" STUDY_ID="STD-Borden-1990" TOTAL_1="171" TOTAL_2="176" VAR="0.08254688630419055" WEIGHT="18.25722248458508"/>
<DICH_DATA CI_END="1.3495300029871973" CI_START="0.32430211264317677" EFFECT_SIZE="0.6615553121577218" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="83" LOG_CI_END="0.13018254431079052" LOG_CI_START="-0.48905022213712473" LOG_EFFECT_SIZE="-0.1794338389131671" ORDER="56" O_E="0.0" SE="0.36374039226313504" STUDY_ID="STD-Edmonson-1993" TOTAL_1="184" TOTAL_2="95" VAR="0.13230707296373936" WEIGHT="11.76811815253941"/>
<DICH_DATA CI_END="1.753611006733394" CI_START="0.3350439237078051" EFFECT_SIZE="0.7665094339622641" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="53" LOG_CI_END="0.24393326271016885" LOG_CI_START="-0.4748982539378853" LOG_EFFECT_SIZE="-0.11548249561385826" ORDER="57" O_E="0.0" SE="0.42224519115246156" STUDY_ID="STD-Muss-1985" TOTAL_1="66" TOTAL_2="66" VAR="0.17829100145137883" WEIGHT="7.700893408193667"/>
<DICH_DATA CI_END="1.251288330954714" CI_START="0.3786524037311291" EFFECT_SIZE="0.6883337375697308" ESTIMABLE="YES" EVENTS_1="129" EVENTS_2="133" LOG_CI_END="0.09735739451705866" LOG_CI_START="-0.4217592818768652" LOG_EFFECT_SIZE="-0.16220094367990323" ORDER="58" O_E="0.0" SE="0.3049317053827821" STUDY_ID="STD-Omura-1983" TOTAL_1="160" TOTAL_2="155" VAR="0.09298334494765181" WEIGHT="15.689964903046155"/>
<DICH_DATA CI_END="1.4410608415996777" CI_START="0.6895812873568922" EFFECT_SIZE="0.9968593633556904" ESTIMABLE="YES" EVENTS_1="307" EVENTS_2="202" LOG_CI_END="0.15868231711739605" LOG_CI_START="-0.16141453214260684" LOG_EFFECT_SIZE="-0.0013661075126053866" ORDER="59" O_E="0.0" SE="0.18802647376028409" STUDY_ID="STD-Santoro-1995" TOTAL_1="400" TOTAL_2="263" VAR="0.035353954834726795" WEIGHT="33.96565395777317"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>